Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/3115
Título : Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol
Autor : Romero, Miguel
Suárez-de-Lezo, José
Herrera, Concha
Pan, Manuel
López-Aguilera, José
Suárez-de-Lezo Jr, José
Baeza-Garzón, Flor
Hidalgo-Lesmes, Francisco Javier
Fernández-López, Olga
Martínez-Atienza, Juliana
Cebrián, Eva
Martín-Palanco, Vanesa
Jiménez-Moreno, Rosario
Gutiérrez-Fernández, Rosario
Nogueras, Sonia
Carmona, Maria Dolores
Ojeda, Soledad
Cuende, Natividad
Mata, Rosario
Filiación: [Romero,M; Suárez-de-Lezo;J; Pan,M; López-Aguilera,J; Suárez-de-Lezo Jr,J; Baeza-Garzón,F; Hidalgo-Lesmes,FJ; Cebrián,E; Ojeda,S] Cardiology Unit, Reina Sofía University Hospital, Córdoba, Spain. [Herrera,C; Martín-Palanco,V; Jiménez-Moreno,R; Gutiérrez-Fernández,R; Nogueras,S; Carmona,MD] Cell Production Unit, Reina Sofía University Hospital, Córdoba, Spain. [Fernández-López,O; Martínez-Atienza,J; Cuende,N; Mata,R] Andalusian Initiative for Advanced Therapies, Andalusian Public Foundation Progress and Health, Seville, Spain.
Palabras clave : Bone marrow mononuclear cells
Cell therapy
Dilated myocardiopathy
Randomized controlled trial
Bone Marrow Cells
Cell- and tissue-based therapy
Cardiomyopathy, Dilated
Células de la médula ósea
Tratamiento basado en trasplante de células y tejidos
Cardiomiopatía dilatada
Ensayo clínico controlado aleatorio
MeSH: Medical Subject Headings::Anatomy::Cells::Bone Marrow Cells
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy
Medical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies::Cardiomyopathy, Dilated
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic
Medical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research
Medical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Myocardial Ischemia::Myocardial Infarction
Medical Subject Headings::Information Science::Information Science::Communications Media::Publications
Fecha de publicación : 22-Aug-2019
Editorial : BioMed Central
Cita Bibliográfica: Romero M, Suárez-de-Lezo J, Herrera C, Pan M, López-Aguilera J, Suárez-de-Lezo Jr J, et al. Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol. BMC Cardiovasc Disord. 2019 Aug 22;19(1):203. doi: 10.1186/s12872-019-1182-4
Abstract: Background Cellular therapies have been increasingly applied to diverse human diseases. Intracoronary infusion of bone marrow-derived mononuclear cells (BMMNC) has demonstrated to improve ventricular function after acute myocardial infarction. However, less information is available about the role of BMMNC therapy for the treatment of dilated myocardiopathies (DCs) of non-ischemic origin. This article presents the methodological description of a study aimed at investigating the efficacy of intracoronary injection of autologous BMMNCs in the improvement of the ventricular function of patients with DC. Methods This randomised, placebo-controlled, double-blinded phase IIb clinical trial compares the improvement on ventricular function (measured by the changes on the ejection fraction) of patients receiving the conventional treatment for DC in combination with a single dose of an intracoronary infusion of BMMNCs, with the functional recovery of patients receiving placebo plus conventional treatment. Patients assigned to both treatment groups are monitored for 24 months. This clinical trial is powered enough to detect a change in Left Ventricular Ejection Fraction (LVEF) equal to or greater than 9%, although an interim analysis is planned to re-calculate sample size. Discussion The study protocol was approved by the Andalusian Coordinating Ethics Committee for Biomedical Research (Comité Coordinador de Ética en Investigación Biomédica de Andalucia), the Spanish Medicines and Medical Devices Agency (Agencia Española de Medicamentos y Productos Sanitarios), and is registered at the EU Clinical Trials Register (EudraCT: 2013–002015-98). The publication of the trial results in scientific journals will be performed in accordance with the applicable regulations and guidelines to clinical trials. Trial registration ClinicalTrials.gov Identifier NCT02033278 (First Posted January 10, 2014): https://clinicaltrials.gov/ct2/show/NCT02033278; EudraCT number: 2013–002015-98, EU CT Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002015-98. Trial results will also be published according to the CONSORT statement at conferences and reported peer-reviewed journals.
URI: http://hdl.handle.net/10668/3115
Versión del editor : https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-019-1182-4
DOI: 10.1186/s12872-019-1182-4
ISSN : 1471-2261
Appears in Collections:01- Artículos - Hospital Reina Sofía
01- Artículos - Red Andaluza de Diseño y Traslación de Terapias Avanzadas

Files in This Item:
File Description SizeFormat 
Romero_RandomisedDoubleBlind.pdfArtículo publicado1,53 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons